CABA stock forecast, quote, news & analysis
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases... Show more
Why Cabaletta Bio (CABA) Stock Is Down -27% in the Last 30 Days
Key Takeaways
- Cabaletta Bio shares fell roughly 27% over the last 30 days, declining from a closing price near $2.00 to about $1.45, and are trading near their 52-week low.
- The decline has been driven primarily by ongoing shareholder dilution from warrant exercises, a reiterated going-concern disclosure, and the withdrawal of the RESET-MS multiple sclerosis study, which narrowed near-term pipeline optionality.
- The broader three-month trend is also negative, with the stock down roughly 47% from late-July levels even after a mid-summer rally that briefly carried shares above $3.30.
- Cabaletta remains a pre-revenue, clinical-stage biotechnology company with no approved products, so its valuation depends heavily on clinical milestones, cash runway, and financing conditions.
- Encouraging rese-cel data across myositis, systemic sclerosis, lupus, and pemphigus vulgaris continue to anchor the bullish case, while financing and execution risks weigh on sentiment.
- For more detail on valuation and upcoming catalysts, visit the Price Targets, Earnings, and Forecast pages.
- To see automated trading strategies focused on this and other tickers, explore Trending AI Robots.
Cabaletta Bio (CABA) Company Overview and Market Position
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on engineered T cell therapies designed to provide deep, durable, and potentially curative responses for patients with autoimmune diseases. Its lead product candidate, rese-cel (resecabtagene autoleucel, formerly CABA-201), is a fully human CD19-directed CAR T cell therapy being evaluated across a portfolio of autoimmune indications, including myositis, systemic sclerosis, systemic lupus erythematosus, lupus nephritis, myasthenia gravis, and pemphigus vulgaris.
The company's proprietary "Cabaletta Approach to B cell Ablation" (CABA) platform encompasses both chimeric antigen receptor T (CAR T) and chimeric autoantibody receptor T (CAAR T) strategies. Investors follow CABA because it represents a high-risk, high-reward wager on the application of cell therapy beyond oncology into large autoimmune markets, where a one-time treatment could potentially reset the immune system. The company is pre-revenue and has no approved products, meaning share performance is driven by clinical data readouts, regulatory progress, and its ability to fund continued development.
Cabaletta Bio (CABA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CABA has declined approximately 27%. The stock closed near $2.00 on September 28 and has since trended lower to roughly $1.45, marking fresh lows near the bottom of its 52-week range. The move reflects sustained selling pressure rather than a single-day shock, with the shares making a series of lower highs and lower lows through October.
The quarterly picture is similarly weak. Three months earlier, in late July, the stock traded around $2.72 before rallying to a peak above $3.30 in late August. Since then, the shares have given back those gains and more, leaving the stock down roughly 47% over the quarter. The contrast between the late-summer strength and the subsequent sell-off highlights how quickly sentiment can shift in a catalyst-dependent, pre-revenue biotech.
What Drove CABA Stock Price in the Last 30 Days
Several verified factors contributed to the recent decline. First, shareholder dilution has been a persistent overhang. Between July and mid-September, Cabaletta reported the exercise of roughly 46 million common stock warrants at an exercise price of $2.50 per share, generating approximately $115 million in gross proceeds but meaningfully increasing the outstanding share count. As the stock fell below that exercise price, dilution concerns intensified.
Second, financing and balance-sheet risks remain in focus. The company's auditor included a going-concern disclosure in the annual report, and management has reiterated that substantial doubt exists about its ability to continue operations without additional funding, with cash expected to fund operations into mid-2027.
Third, Cabaletta withdrew the planned RESET-MS trial evaluating rese-cel in multiple sclerosis before dosing began, reducing near-term optionality in a large indication investors had viewed as a potential growth driver. Finally, analyst sentiment turned more cautious, with Wells Fargo lowering its price target to $3.00 and independent ratings firms issuing sell or strong-sell calls, even as the broader sell-side consensus remained a moderate buy.
What Drove CABA Stock Performance Over the Last Quarter
The three-month trend reflects a tug-of-war between encouraging clinical progress and persistent capital-market pressures. During the summer, shares rallied on positive rese-cel updates presented at major medical conferences, including data showing high response rates in myositis, durable responses in systemic sclerosis, and promising preconditioning-free results in pemphigus vulgaris.
That optimism was ultimately overwhelmed by the financing backdrop. The company completed a highly dilutive equity offering in May 2026, and the subsequent wave of warrant exercises further expanded the share count. Combined with the going-concern language and the absence of a near-term registrational data readout — pivotal myositis results are not expected until mid-2027 — investors grew impatient, and the stock gave back its summer gains as a result.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's most relevant and top-performing automated trading strategies. Tickeron offers hundreds of AI-powered trading bots that collectively trade thousands of tickers, but only the bots demonstrating standout performance and current relevance appear in this focused section. The featured bots vary widely in their strategies, timeframes, and performance metrics, allowing traders to compare approaches across different market conditions. For investors tracking volatile, catalyst-driven names like CABA, these tools provide a data-driven way to monitor momentum and identify signals. Explore the section to see which automated strategies are currently drawing attention.
CABA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalysts for CABA are clinical and financial. Investors should monitor updates from the RESET clinical program, including additional preconditioning-free data in pemphigus vulgaris and lupus, as well as progress in the registrational myositis cohort, where a Biologics License Application submission is targeted for the second half of 2027. Automated manufacturing milestones with the Cellares Cell Shuttle platform also matter, given their implications for scalability and cost.
On the financial side, watch for further capital-raising activity, warrant-related dilution, and any updates to the company's cash runway. Analyst rating changes, regulatory guidance from the FDA on trial design, and broader sector sentiment toward cell therapy in autoimmune disease will continue to influence the stock. These factors carry meaningful risk, and outcomes remain uncertain for a pre-revenue biotech with a going-concern disclosure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CABA's RSI Indicator recovers from oversold territory
The RSI Indicator for CABA moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 24 of the 26 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where CABA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on CABA as a result. In 78 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +8.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.216) is normal, around the industry mean (3.162). P/E Ratio (-1.094) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases
Industry Biotechnology